These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6468474)

  • 1. Effect of liver failure on the pharmacokinetics of cyclophosphamide.
    Juma FD
    Eur J Clin Pharmacol; 1984; 26(5):591-3. PubMed ID: 6468474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.
    Juma FD; Rogers HJ; Trounce JR
    Eur J Clin Pharmacol; 1981; 19(6):443-51. PubMed ID: 7250178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of xamoterol in liver disease.
    Nicholls DP; Taggart AJ; McCann JP; Bastain W; Shanks RG
    Br J Clin Pharmacol; 1989 Dec; 28(6):718-21. PubMed ID: 2532923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration.
    Juma FD; Rogers HJ; Trounce JR
    Br J Clin Pharmacol; 1979 Sep; 8(3):209-17. PubMed ID: 497087
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacokinetics of cefoperazone in liver diseases].
    Kakiuchi S; Tagawa S; Tameda Y; Kosaka Y
    Jpn J Antibiot; 1985 Aug; 38(8):2026-32. PubMed ID: 4078997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction.
    Farthing MJ; Alstead EM; Abrams SM; Haug G; Johnston A; Hermann R; Niebch G; Ruus P; Molz KH; Turner P
    Postgrad Med J; 1994 May; 70(823):363-6. PubMed ID: 8016009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium).
    Roberts RK; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1978 Sep; 75(3):479-85. PubMed ID: 680505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cyclophosphamide in Kenyan Africans.
    Juma F; Ogada T
    Br J Clin Pharmacol; 1983 Jul; 16(1):61-3. PubMed ID: 6882623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The disposition of intravenous L-tryptophan in healthy subjects and in patients with liver disease.
    Rössle M; Herz R; Mullen KD; Jones DB
    Br J Clin Pharmacol; 1986 Dec; 22(6):633-8. PubMed ID: 3567009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing diazepam pharmacokinetics: age, sex, and liver disease.
    Greenblatt DJ; Harmatz JS; Shader RI
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):177-9. PubMed ID: 649236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cimetidine in patients with liver disease.
    González-Martin G; Arancibia A; Fajuri M; Chesta J; Novoa X
    Int J Clin Pharmacol Ther Toxicol; 1985 Jul; 23(7):355-8. PubMed ID: 4030163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
    Kirch W; Rose I; Demers HG; Leopold G; Pabst J; Ohnhaus EE
    Clin Pharmacokinet; 1987 Aug; 13(2):110-7. PubMed ID: 2887325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The disposition of cyclophosphamide in a group of myeloma patients.
    Bramwell V; Calvert RT; Edwards G; Scarffe H; Crowther D
    Cancer Chemother Pharmacol; 1979; 3(4):253-9. PubMed ID: 535136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of guanabenz in patients with impaired liver function.
    Lasseter KC; Shapse D; Pascucci VL; Chiang ST
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S766-70. PubMed ID: 6084122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment.
    Blake JC; Palmer JL; Minton NA; Burroughs AK
    Br J Clin Pharmacol; 1993 Apr; 35(4):441-3. PubMed ID: 8485026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.
    Breyer-Pfaff U; Seyfert H; Weber M; Egberts EH
    Eur J Clin Pharmacol; 1984; 26(1):95-101. PubMed ID: 6143671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.